19 May 2013
Keywords: entremed, starts, ph, i/ii, trial, endostatin, enrolled
Article | 13 July 2001
EntreMed has enrolled the first patients into its Phase I/II trial ofits angiogenesis inhibitor, recombinant human endostatin, which is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 July 2001
11 July 2001
17 May 2013
© 2013 thepharmaletter.com